Published in J Exp Med on November 02, 1998
Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med (2000) 2.18
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem (2005) 1.92
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity. PLoS Biol (2008) 1.57
Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper. Nat Rev Immunol (2009) 1.49
Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology (2008) 1.47
CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery. Proc Natl Acad Sci U S A (2010) 1.28
Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol (2003) 1.27
The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function. Immunogenetics (2007) 1.20
Sustained interactions between T cell receptors and antigens promote the differentiation of CD4⁺ memory T cells. Immunity (2013) 1.03
Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res (2009) 1.03
Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med (1999) 1.00
Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers. BMC Immunol (2011) 0.97
Double negative (DN) αβ T cells: misperception and overdue recognition. Immunol Cell Biol (2014) 0.96
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog (2008) 0.95
T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. Biophys J (2001) 0.94
Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity. J Exp Med (2001) 0.93
The dendritic cell cytoskeleton promotes T cell adhesion and activation by constraining ICAM-1 mobility. J Cell Biol (2015) 0.92
Anergy induction by dimeric TCR ligands. J Immunol (2001) 0.91
Action and Traction: Cytoskeletal Control of Receptor Triggering at the Immunological Synapse. Front Immunol (2016) 0.91
Direct staining with major histocompatibility complex class II dextramers permits detection of antigen-specific, autoreactive CD4 T cells in situ. PLoS One (2014) 0.87
Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther (2005) 0.86
MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides. PLoS One (2013) 0.83
Development and use of multimeric major histocompatibility complex molecules. Clin Diagn Lab Immunol (2002) 0.81
Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochim Biophys Acta (2014) 0.81
Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response. Front Immunol (2015) 0.80
Double-Negative αβ T Cells Are Early Responders to AKI and Are Found in Human Kidney. J Am Soc Nephrol (2015) 0.78
Major Histocompatibility Complex Class II Dextramers: New Tools for the Detection of antigen-Specific, CD4 T Cells in Basic and Clinical Research. Scand J Immunol (2015) 0.75
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature (1995) 7.40
Selective development of CD4+ T cells in transgenic mice expressing a class II MHC-restricted antigen receptor. Nature (1989) 5.80
T cell activation determined by T cell receptor number and tunable thresholds. Science (1996) 5.51
Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature (1987) 5.24
Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol (1998) 5.11
The major histocompatibility complex-restricted antigen receptor on T cells. II. Role of the L3T4 product. J Exp Med (1983) 3.54
CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature (1996) 3.08
Production of soluble MHC class II proteins with covalently bound single peptides. Nature (1994) 2.98
Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature (1987) 2.89
Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells. Cell (1991) 2.79
Dimeric association and segmental variability in the structure of human CD4. Nature (1997) 2.35
The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol (1992) 2.34
CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature (1995) 2.15
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A (1998) 1.95
Ligand-specific oligomerization of T-cell receptor molecules. Nature (1997) 1.58
Antigen recognition properties of mutant V beta 3+ T cell receptors are consistent with an immunoglobulin-like structure for the receptor. J Exp Med (1993) 1.40
The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med (1997) 1.33
Quantitative contribution of CD4 and CD8 to T cell antigen receptor serial triggering. J Exp Med (1997) 1.26
Transferable anergy: superantigen treatment induces CD4+ T cell tolerance that is reversible and requires CD4-CD8- cells and interferon gamma. J Exp Med (1997) 1.15
Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness. J Exp Med (1995) 1.13
T cell positive selection by a high density, low affinity ligand. Proc Natl Acad Sci U S A (1998) 1.12
The major histocompatibility complex-restricted antigen receptor on T cells. IX. Role of accessory molecules in recognition of antigen plus isolated IA. J Immunol (1986) 1.07
Distinct roles for CD4 and CD8 as co-receptors in T cell receptor signalling. Eur J Immunol (1994) 0.98
Mouse CD4 binds MHC class II with extremely low affinity. Int Immunol (1993) 0.97
Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays. J Exp Med (1992) 0.92
How T cells count. Science (1996) 0.91
Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors. J Exp Med (1997) 0.91
T-cell receptors. Serial engagement proposed. Nature (1995) 0.88
Analogs that compete for antigen binding to an arsonate-reactive T-cell clone inhibit the functional response to arsonate. Cell (1984) 0.85
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell (1991) 2.23
Characterization of murine thymocytes with CD3-associated T-cell receptor structures. Nature (1987) 1.83
A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med (1995) 1.78
Lateral diffusion of GFP-tagged H2Ld molecules and of GFP-TAP1 reports on the assembly and retention of these molecules in the endoplasmic reticulum. Immunity (1999) 1.52
Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol (1999) 1.51
Sinus augmentation. Rationale, development, long-term results. N Y State Dent J (1993) 1.49
Peripheral murine CD3+, CD4-, CD8- T lymphocytes express novel T cell receptor gamma delta structures. J Immunol (1988) 1.23
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther (1998) 1.07
Trifluoperazine inhibits phagocytosis in a macrophagelike cultured cell line. J Cell Biol (1981) 1.06
Genetic analysis of the role of cAMP in mediating effects of interferon. Proc Natl Acad Sci U S A (1982) 1.01
Genetic approaches to the mechanism of macrophage functions. Fed Proc (1978) 0.99
T cells and tumours. Nature (2001) 0.98
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol (2000) 0.96
Properties of protein kinase and adenylate cyclase-deficient variants of a macrophage-like cell line. J Cell Physiol (1979) 0.96
Evidence that mismatched bases in heteroduplex T4 bacteriophage are recognized in vivo. J Virol (1976) 0.94
Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cell Immunol (1999) 0.94
Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity. J Exp Med (2001) 0.93
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92
Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors. J Exp Med (1997) 0.91
Inhibition of plasminogen activator secretion by cyclic AMP in a macrophage-like cell line. J Cyclic Nucleotide Res (1978) 0.90
Facial nerve injury during surgery of the temporomandibular joint: a comparison of two dissection techniques. J Oral Maxillofac Surg (1985) 0.88
Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res (1995) 0.87
Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Clin Cancer Res (2001) 0.86
CD8 expression alters the fine specificity of an alloreactive MHC class I-specific T hybridoma. Int Immunol (1992) 0.86
Differential effects of a saturated and a monounsaturated fatty acid on MHC class I antigen presentation. Scand J Immunol (2008) 0.86
Modulation of Fc-receptor expression and Fc-mediated phagocytosis in variants of a macrophage-like cell line. J Immunol (1981) 0.85
Monitoring antigen-specific T cells using MHC-Ig dimers. Curr Protoc Immunol (2001) 0.84
Dehydrogenases involved in the conversion of succinate to 4-hydroxybutanoate by Clostridium kluyveri. Appl Environ Microbiol (1993) 0.82
Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase. Hum Antibodies (2007) 0.82
Taming the sinister side of BMT: Dr. Jekyll and Mr. Hyde. Nat Med (1997) 0.82
Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. Int Immunol (1993) 0.81
Rat liver ATP synthase. Relationship of the unique substructure of the F1 moiety to its nucleotide binding properties, enzymatic states, and crystalline form. J Biol Chem (1995) 0.80
Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine (2001) 0.78
Activation of phosphoinositide-specific phospholipase C delta from rat liver by polyamines and basic proteins. Arch Biochem Biophys (1991) 0.77
Mandibular tumorous condition in a 9-week-old child. J Oral Pathol (1978) 0.76
Anatomic considerations for dental implants. J Oral Implantol (1991) 0.76
Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found Symp (1994) 0.76
A simple method for sialography. J Oral Surg (1978) 0.75
Clinicopathologic conferences. Case 38, Part I. J Oral Maxillofac Surg (1982) 0.75
NMR docking of a substrate into the X-ray structure of the Asp-21-->Glu mutant of staphylococcal nuclease. Biochemistry (1994) 0.75
Preoperative assessment for practicing oral and maxillofacial surgeons. J Dent Educ (1982) 0.75
Ramus frame--revisited. J Oral Implantol (1996) 0.75
A peptide derived from the alpha-helical region of class I MHC blocks CTL engagement of the class I MHC molecule. Cold Spring Harb Symp Quant Biol (1989) 0.75
Reactivity of pyridoxal 5-phosphate residues of cystathionase. Biochim Biophys Acta (1971) 0.75
Molecular analysis of a pro-T cell clone transformed by Abelson-murine leukemia virus, displaying progressive gamma delta T cell receptor gene rearrangement and surface expression. Eur J Immunol (1992) 0.75
Multiple keratocysts syndrome: report of case. ASDC J Dent Child (1979) 0.75
Effect of x rays on developing cysticercoids of Hymenolepis microstoma. Radiat Res (1971) 0.75
Clinicopathologic conferences. Case 38, part II: Aneurysmal bone cyst of the mandible. J Oral Maxillofac Surg (1982) 0.75
Oral and maxillofacial surgery: a review of the literature. Fla Dent J (1980) 0.75
Immunochemical analysis of a recombinant, genetically engineered, secreted HLA-A2/Q10b fusion protein. Hum Immunol (1991) 0.75